T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Pipeline Review, H2 2018
T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Cluster of differentiation 80 or CD80 or B7-1 is a protein found on dendritic cells, activated B cells and monocytes. The activated protein induces T-cell proliferation and cytokine production. T-cell proliferation and cytokine production is induced by the binding of CD28.
T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) pipeline Target constitutes close to 10 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 2, 3 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Immunology, Oncology, Musculoskeletal Disorders, Central Nervous System, Dermatology, Genito Urinary System And Sex Hormones, Hematological Disorders, Metabolic Disorders, Ophthalmology and Respiratory which include indications Rheumatoid Arthritis, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Alopecia, Breast Cancer, Cytopenia, Dermatomyositis, Focal Segmental Glomerulosclerosis (FSGS), Graft Versus Host Disease (GVHD), Granulomatosis with Polyangiitis (Wegener's Granulomatosis), Hepatocellular Carcinoma, Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease), Juvenile Rheumatoid Arthritis, Kidney Transplant Rejection, Lupus Nephritis, Myasthenia Gravis, Nephrotic Syndrome, Polyarticular Juvenile Idiopathic Arthritis (PJIA), Polymyalgia Rheumatica (PMR), Polymyositis/Idiopathic Inflammatory Myopathy, Sicca Syndrome (Sjogren), Systemic Lupus Erythematosus, Systemic Sclerosis (Scleroderma), Type 1 Diabetes (Juvenile Diabetes), Uveitis and Vitiligo.
The latest report T Lymphocyte Activation Antigen CD80 - Pipeline Review, H2 2018, outlays comprehensive information on the T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook